Clinical Research Directory
Browse clinical research sites, groups, and studies.
Glycemic Control with Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Sponsor: Nabiqasim Industries (Pvt) Ltd
Summary
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
Official title: Glycemic Control with Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
800
Start Date
2025-04
Completion Date
2026-04
Last Updated
2025-03-06
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin+Linagliptin+Metformin
Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients